Evidence map›Paper›PMID 42116640›Full record

ReviewJournal of paediatrics and child health2026

Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania.

Cecilia Verryt, Paul Gray, Peter McNaughton, Jane Peake, Melanie Wong, George Aho, Emma Best, Maia Brewerton, Flora Lutui, Litara Esera Tulifau and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of paediatrics and child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Cecilia VerrytDepartment of Clinical Immunology & Allergy, Starship Children's Hospital, Auckland, New Zealand.ORCID https://orcid.org/0009-0008-8188-232X
Paul GraySydney Children's Hospital, Randwick, New South Wales, Australia.
Peter McNaughtonQueensland Paediatric Immunology and Allergy Service, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
Jane PeakeQueensland Paediatric Immunology and Allergy Service, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
Melanie WongThe Children's Hospital at Westmead, Westmead, New South Wales, Australia.
George AhoPaediatric Department, Vaiola Hospital, Ministry of Health, Nukualofa, Tonga.
Emma BestDepartment of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.
Maia BrewertonDepartment of Clinical Immunology & Allergy, Auckland City Hospital, Auckland, New Zealand.
Flora LutuiPaediatric Department, Vaiola Hospital, Ministry of Health, Nukualofa, Tonga.
Litara Esera TulifauTupua Tamasese Meaole Hospital, Apia, Samoa.
Rebecca QinDepartment of Allergy and Clinical Immunology, Women's and Children's Hospital, North Adelaide, Australia.
Satupa'itea VialiOceania University of Medicine, Apia, Samoa.
Petine WhiteDepartment of Clinical Immunology & Allergy, Starship Children's Hospital, Auckland, New Zealand.
Andrew WoodDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
See-Tarn WoonDepartment of Microbiology and Immunology, LabPLUS, Health New Zealand, Auckland, New Zealand.
Theresa ColeDepartment of Immunology and Allergy, Royal Children's Hospital, Parkville, Victoria, Australia.
Alberto Pinzon CharryQueensland Paediatric Immunology and Allergy Service, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
Kuang-Chih HsiaoDepartment of Clinical Immunology & Allergy, Starship Children's Hospital, Auckland, New Zealand.ORCID https://orcid.org/0000-0001-7412-9761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life-threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due to being homozygous for or having two copies of the regionally relevant pathogenic IFNAR1 variant c.1156G>T, p.Glu386*. IFNAR1 deficiency confers an increased risk of severe and life-threatening infections caused by naturally circulating viruses including influenza, SARS-CoV-2, herpes simplex virus, respiratory syncytial virus (RSV), arboviruses and viruses in live attenuated vaccines (LAVs) including measles-mumps-rubella (MMR) and yellow fever. Complications including virus induced systemic hyperinflammation (VISH) are associated with significant mortality. This document outlines expert consensus regarding early identification, diagnostic workup and management of IFNAR1 deficiency in Australia, Aotearoa New Zealand and Western Pacific nations.

Indexed as

Receptor, Interferon alpha-betaVirus DiseasesAustraliaHumansOceaniaPractice Guidelines as TopicIFNAR1 protein, humanReceptor, Interferon alpha-beta

Identifiers

PMID42116640
PMCPMC13378212

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.